Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC

Inclusion Criteria (Main): * Histologically or cytologically proven Pancreatic Adenocarcinoma. * Stage of disease defined as unresectable Locally Advanced Pancreatic Cancer. * No prior radiotherapy for pancreatic cancer. * Target tumour with a minimum diameter of 2.6 cm and a volume of from 9 to 34 ml. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Patient has acceptable hematological parameters including white and red blood counts, liver and renal function that makes them suitable to receive SoC chemotherapy as per local clinical practice. * Life expectancy of ≥6 months at screening. Exclusion Criteria (Main): * Evidence of distant metastases based on the restaging process after two months of induction chemotherapy identified using CT/MRI/18 FDG PET assessment. * Evidence of switch from unresectable status to resectable status of disease after two months of induction chemotherapy. * More than one primary lesion, if one of the primary lesions is not a good candidate for debulking with YntraDose™, due to clinical reasons and/or decision made by the local MDTB. * ECOG is higher than 1. * History of malignancy in the last 3 years. * Blood clotting disorders (INR \> 1.5, PLT \< 50,000/µl - risk of bleeding during organ puncture). * Active systemic or local infection (e.g. peritonitis, abscess). * Severe organ failure (e.g. end-stage liver, kidney, heart failure). * Cardiological and other diseases that threaten the use of anesthesia. * Pancreatitis (acute or exacerbation of chronic inflammation).